Article: FDA-SEC partnership raises questions about disclosure of development and trial reports.(Drug development)

WASHINGTON -- FDA's efforts to have drug and biologics makers disclose their "development reports" as part of the agency's drug quality initiative could present some exposure industry had not realized due to the agency's new working agreement with the Securities and Exchange Commission (SEC).

Addressing the Food and Drug Law Institute's (FDLI) 47th Annual Conference here April 15, private industry and SEC attorneys agreed that should a company's development report be disclosed, it could have an impact on stock price and thus pose enforcement actions from two agencies.

FDA and SEC solidified their relationship February 2004 and laid out specific areas ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!